Dr. Sarah E. Leary, MD
- Publications
- 93
- Clinical trials
- 11
- Hospital affiliations
- 1
- Industry payments
- $79
- Medical group
- 1
- Practice address
- 4800 Sand Point Way NE, PO Box C-5371, Seattle, WA 98105
- Practice phone
- Call (206) 987-2000
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Leary's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Sarah E. Leary is a pediatric hematology and oncology physician in Seattle, Washington
Dr. Leary practices at Seattle Children's Hospital in Seattle, Washington, part of Seattle Children's Hospital, Research Institute and Foundation.
Dr. Leary's NPI, 1427268416, was assigned on May 22, 2007. Dr. Leary graduated from University of Tennessee, Hsc, College of Medicine in 2001. Dr. Leary holds Washington license MD60082616.
- NPI
- 1427268416NPI Registry (opens in a new tab)
- NPI enumeration date
- May 22, 2007
- NPI status
- Active
- Practice phone
- (206) 987-2000
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Female
- Estimated age
- 51
- Medical school graduation
- 2001
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Affiliation Data
Dr. Sarah E. Leary practices at Seattle Children's Hospital in Seattle, Washington
Dr. Leary's primary practice is Seattle Children's Hospital, at 4800 Sand Point Way NE, PO Box C-5371, Seattle, WA 98105 in King County. The practice phone is (206) 987-2000.
- Seattle Children's Hospital4800 Sand Point Way NE, PO Box C-5371, Seattle, WA 98105 · King CountyPhone(206) 987-2000
Source: Dmand AI Affiliation Data
Dr. Sarah E. Leary is affiliated with 1 site of care and 1 medical group
Dr. Leary's primary practice is Seattle Children's Hospital in Seattle, Washington, part of Seattle Children's Hospital, Research Institute and Foundation. The medical group on file is Children's University Medical Group (CUMG).
Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Sarah E. Leary's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Leary practices. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Seattle Children's Hospital | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
Dmand AI maps EHR vendors, IT decision makers and buying committees across Seattle Children's Hospital, Research Institute and Foundation and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Sarah E. Leary is one of 94 pediatric hematologys and oncology physicians in Washington
Pediatric hematology-oncology is Dr. Leary's primary specialty in the NPI Registry, under taxonomy code 2080P0207X. Dr. Leary is licensed in Washington.
Specialties and state licenses
- Pediatric hematology and oncology, WashingtonPrimary
Pediatric hematologys and oncology physicians near Dr. Leary
Counts of pediatric hematologys and oncology physicians with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Sarah E. Leary's patients have a median age of 14
Across all payers, Dmand AI patient panel data puts Dr. Leary's median patient age at 14, with 48% women.
Dr. Leary's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 14
Patient panel by sex, all payers
- Women48%
- Men51%
Source: Dmand AI Patient Panel Data
Dr. Sarah E. Leary has 93 publications on record
Dmand AI links 93 papers to Dr. Leary, published from 2011 to 2025. 2020 was the busiest year, with 8. The most frequent topics are Brain Neoplasms, Glioma and Medulloblastoma. Dr. Leary has published most often in Neuro Oncol. Dr. Leary's most frequent co-authors are Erin E. Crotty, MD, Roger Packer, MD and Nicholas Alexander Vitanza, MD.
Dr. Leary's papers by year, 2016 to 2025
Topics Dr. Leary writes about most
- Brain Neoplasms
- Glioma
- Medulloblastoma
- Brain Stem Neoplasms
- Cerebellar Neoplasms
- Diffuse Intrinsic Pontine Glioma
- Biomarkers, Tumor
- Central Nervous System Neoplasms
Dr. Leary's most frequent co-authors
- Erin E. Crotty, MD16 shared papers
- Roger Packer, MD14 shared papers
- Nicholas Alexander Vitanza, MD13 shared papers
Recent publications by Dr. Leary
See who Dr. Leary researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Leary works with, so you can find a warm path to the right pediatric hematologys and oncology physicians.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Sarah E. Leary has worked on 11 clinical trials
Dmand AI links Dr. Leary to 11 clinical trials, 7 of them phase 3 studies. 10 are still active or recruiting. Conditions studied include Ganglioneuroblastoma, Neuroblastoma and Carcinoma, Renal Cell. Children's Oncology Group sponsors the most, 6. Open Payments lists research payments to Dr. Leary that name 1 trial.
Clinical trials with Dr. Leary by phase
- NonePhase 1: no trials
- 3Phase 2: 3 trials
- 7Phase 3: 7 trials
- NonePhase 4: no trials
Conditions in Dr. Leary's trials
- Ganglioneuroblastoma
- Neuroblastoma
- Carcinoma, Renal Cell
- Hematologic Neoplasms
- Hodgkin Disease
Investigators on the most trials with Dr. Leary
- Sandeep Batra, MD8 shared trials
- Chana L. Glasser, MD8 shared trials
- Duncan Scott Stearns, MD8 shared trials
Recent clinical trials with Dr. Leary
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations (opens in a new tab)
Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study (opens in a new tab)
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia (opens in a new tab)
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (opens in a new tab)
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) (opens in a new tab)
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Sarah E. Leary received $79 in industry payments from 2016 to 2025
CMS Open Payments shows 2 general payments to Dr. Leary from 2 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Novartis Pharmaceuticals Corporation paid the most, $61. It also lists 3 research payments totaling $1,334 in 2017, naming 1 clinical trial.
General payments to Dr. Leary by program year, 2016 to 2025
Companies that paid Dr. Leary the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Sarah E. Leary graduated from University of Tennessee, Hsc, College of Medicine
Dr. Leary graduated from University of Tennessee, Hsc, College of Medicine in 2001.
- Medical school
Source: Dmand AI Professional Profile Data
Sources for Dr. Sarah E. Leary's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel Data |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Sarah E. Leary
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Sarah E. Leary's NPI number?
Dr. Sarah E. Leary's NPI number is 1427268416. It was assigned on May 22, 2007, and it is active in the NPI Registry.
What kind of doctor is Dr. Sarah E. Leary?
Dr. Sarah E. Leary is a pediatric hematology and oncology physician in Seattle, Washington. The primary specialty in the NPI Registry is Pediatric Hematology & Oncology Physician (taxonomy code 2080P0207X).
Where does Dr. Sarah E. Leary practice?
Dr. Leary practices at 4800 Sand Point Way NE, PO Box C-5371, Seattle, WA 98105. Dr. Leary's primary practice is Seattle Children's Hospital in Seattle, Washington, part of Seattle Children's Hospital, Research Institute and Foundation.
What is Dr. Sarah E. Leary's office phone number?
The practice phone on file for Dr. Leary is (206) 987-2000.
What is Dr. Sarah E. Leary's medical license number?
Dr. Leary holds Washington license MD60082616.
Which hospitals is Dr. Sarah E. Leary affiliated with?
Dr. Leary practices at Seattle Children's Hospital in Seattle, Washington.
What medical group is Dr. Sarah E. Leary part of?
Dr. Leary is linked to Children's University Medical Group (CUMG).
Where did Dr. Sarah E. Leary go to medical school?
Dr. Leary graduated from University of Tennessee, Hsc, College of Medicine in 2001.
Has Dr. Sarah E. Leary received payments from drug or device companies?
CMS Open Payments shows $79 in general payments to Dr. Leary from 2 companies from 2016 to 2025. The largest total came from Novartis Pharmaceuticals Corporation.
How long has Dr. Sarah E. Leary been practicing?
Dr. Leary graduated from medical school in 2001, 25 years ago.
Does Dr. Sarah E. Leary do research?
Dmand AI links 93 publications to Dr. Leary, published from 2011 to 2025. Dr. Leary has worked on 11 clinical trials.
Who does Dr. Sarah E. Leary publish with?
Dr. Leary's most frequent co-authors are Erin E. Crotty, MD (16 shared papers), Roger Packer, MD (14 shared papers) and Nicholas Alexander Vitanza, MD (13 shared papers).
Selling to pediatric hematology-oncology practices?
See pediatric hematologys and oncology physicians in Washington by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card